

## Special Issue

# Advances in Vaccine Adjuvant/Delivery System

### Message from the Guest Editor

Vaccine adjuvant/immunomodulator and delivery systems (VADSs), either directly or indirectly, have become integral components of many vaccines. At present, a variety of vaccines, based on RNA, DNA, recombinant proteins, inactivated and attenuated viruses, or viral vectors, are being tested with a variety of VADSs. Although the exact mechanism of action of many adjuvants and VADSs remains unknown, they provide a lasting immune memory and enhanced efficacy of vaccines by modulating innate and adaptive immune responses and promoting immune responses to antigens. The purpose of this Special Issue is to present the latest developments in vaccine adjuvant and delivery systems (VADSs). We invite potential researchers to submit an article, review, etc., on the mechanisms and actions of vaccine adjuvants and VADSs and their recent developments. Priority will be given to articles that focus on newly emerging or highly dangerous infectious agents in humans or animals (e.g., coronavirus, influenza, hepatitis, dengue, malaria, HIV, RSV, etc.). I look forward to receiving your contributions.

---

### Guest Editor

Dr. Ting Wang

School of Pharmacy, Anhui Medical University, Hefei 230000, China

---

### Deadline for manuscript submissions

closed (15 January 2023)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/120968](https://mdpi.com/si/120968)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).